Figure S3.
The process begins with the identification of studies via databases. Records identified from database searches in PubMed total 73. These records are then screened, with all 73 records being screened. Reports sought for retrieval also total 73. These reports are assessed for eligibility, with all 73 reports being assessed. Reports are excluded for various reasons: absence or indeterminate use of r h G-C S F or r h G M-C S F (60 reports), duplicates (1 report), and r h G-C S F administration following transplantation (1 report). Finally, 11 studies are included in the review.
PRISMA flow diagram for literature review on the significance of rhG-CSF/rhGM-CSF in patients with RD. We reviewed 73 articles with the term reticular dysgenesis extracted from PubMed by February 2025, and identified 11 literature papers describing a total of 12 patients with RD who received rhG-CSF (n = 11) or rhGM-CSF (n = 1). RD, reticular dysgenesis; rhG-CSF, recombinant human granulocyte colony-stimulating factor; rhGM-CSF, recombinant human granulocyte–macrophage colony-stimulating factor.